ArticleWorld journal of surgical oncology2014
Predictors of recurrence after a first hepatectomy for colorectal cancer liver metastases: a retrospective analysis.
Article in World journal of surgical oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- A Systematic Review and Meta-Analysis of Oncologic Liver Resections in Low- and Middle-Income Countries: Opportunities to Improve Evidence and Outcomes.Journal of surgical oncology · 2025Pooled it
- Current opinions on CEA in the diagnosis and prognosis of colorectal cancer.Translational oncology · 2026Review
- Mid-transversal hepatectomy: breaking new ground in parenchymal sparing hepatectomies.Updates in surgery · 2025Article
- Predicting one-year post-surgical recurrence in colorectal liver metastasis using CT radiomics and machine learning.PloS one · 2025Article
- The role of artificial intelligence and image processing in the diagnosis, treatment, and prognosis of liver cancer: a narrative-review.Przeglad gastroenterologiczny · 2024Review
- A Retrospective Study on the Role of Metformin in Colorectal Cancer Liver Metastases.Biomedicines · 2023Article
- Liver Transplantation for Hepatic Metastases from Colorectal Cancer: Current Knowledge and Open Issues.Cancers · 2023Review
- Impact of Preoperative CEA Uptrend on Survival Outcomes in Patients with Colorectal Liver Metastasis After Hepatectomy.Annals of surgical oncology · 2022Article
- Predicting metachronous liver metastasis in patients with colorectal cancer: development and assessment of a new nomogram.World journal of surgical oncology · 2022Article
- Artificial intelligence in the diagnosis and management of colorectal cancer liver metastases.World journal of gastroenterology · 2022Review
- Biomarkers in colorectal liver metastases: Rising complexity and unknown clinical significance?Annals of gastroenterological surgery · 2021Review
- Colorectal liver metastases: Current management and future perspectives.World journal of clinical oncology · 2020Review
- Article
- Molecular Immunotherapy: Promising Approach to Treat Metastatic Colorectal Cancer by Targeting Resistant Cancer Cells or Cancer Stem Cells.Frontiers in oncology · 2020Review
- Article
- The prognostic and therapeutic role of hormones in colorectal cancer: a review.Molecular biology reports · 2019Review
- Recurrence patterns after laparoscopic resection of colorectal liver metastases.Surgical endoscopy · 2018Article
- Colorectal Liver Metastases: Does the Future of Precision Medicine Lie in Genetic Testing?Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2018Review
- The New Era of Transplant Oncology: Liver Transplantation for Nonresectable Colorectal Cancer Liver Metastases.Canadian journal of gastroenterology & hepatology · 2018Review
- Carcinoembryonic antigen testing after curative liver resection for synchronous liver metastasis of colorectal cancer: a Japanese multicenter analysis.Surgery today · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSurgical resection is considered the standard therapy in the treatment of liver metastases from colorectal cancer (CRCLM); however, most patients experience tumor recurrence after curative hepatic resection. The objective was to determine potential prognostic factors for tumor recurrence after an initial hepatectomy for CRCLM.
methodsA study population of 101 patients who had undergone a first curative hepatectomy for CRCLM was retrospectively analyzed. Selected biological tumor markers, and clinical and pathological features were then tested by Cox regression.
resultsSynchronous liver metastases occurred in 38 patients (37.6%) and 63 patients (62.3%) presented with metachronous liver metastases. In a median follow-up time of 68 months, recurrence was observed in 64 patients (63.3%). The 5-year cumulative risk of recurrence was 56.7%. The median survival after recurrence was 24.5 months (range 1 to 41 months) and 5-year cumulative overall survival was 31.8%. Of all variables tested by Cox regression, intra- and extrahepatic resectable disease, CEA levels≥50 ng/mL and bilobar liver disease remained significant as predictors of recurrence in the multivariate analysis.
conclusionsIndependent risk factors for recurrence after an initial hepatectomy for CRCLM, such as intra- and extrahepatic resectable disease, CEA levels≥50 ng/mL and bilobar liver disease, can eventually help in making decisions in this very complex scenario.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.